Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Go back to Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)| COGENT (NASDAQ: COGT) | Delayed: 31.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.50 | 52 Week High | $5.57 | |||
| Open | $31.50 | 52 Week Low | $2.90 | |||
| Day High | $31.50 | P/E | 143.18 | |||
| Day Low | $31.50 | EPS | $0.22 | |||
| Volume | 169 | |||||
